After hours:
Chart Events
Performance Outlook
| Previous Close | 257.83 |
| Open | 258.53 |
| Bid | 256.99 x 800 |
| Ask | 256.60 x 900 |
| Day's Range | 255.25 - 259.23 |
| 52 Week Range | 250.31 - 319.76 |
| Volume | |
| Avg. Volume | 1,004,384 |
| Market Cap | 37.221B |
| Beta (5Y Monthly) | 0.13 |
| PE Ratio (TTM) | 14.04 |
| EPS (TTM) | 18.31 |
| Earnings Date | Oct 23, 2023 - Oct 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 333.66 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BIIB
Related Research
- Biogen Inc.Two-Thirds Through a Positive Investing YearThe Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are Catalent Inc. (CTLT); Splunk Inc (SPLK); Twilio Inc (TWLO); CIENA Corp. (CIEN) and the Focus List deletions are Biogen Inc (BIIB); Arista Networks Inc (ANET); Netflix Inc (NFLX); Shopify Inc (SHOP).RatingFair ValueEconomic Moat17 days agoArgus Research
GlobeNewswireFDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®
TOFIDENCE (BIIB800) becomes the first tocilizumab biosimilar to gain FDA approval in the United StatesFDA approval is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE to the reference product ACTEMRA CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved TOFIDENCE (tocilizumab-bavi) intravenous formulation, a biosimilar monoclonal antibody referencing ACTEMRA.
Investor's Business DailyIs Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone?
Eli Lilly surged 15% in one day on enthusiasm for weight-loss and Alzheimer’s drugs. But is LLY stock a buy now? Here's what you should know.
Motley FoolIs Biogen Stock a Buy Now?
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.
